Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis

Aim: To evaluate the efficacy and safety of lopinavir–ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversio...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Jiawen, Zhou, Fangwen, Hou, Wenteng, Heybati, Kiyan, Ali, Saif, Chang, Oswin, Silver, Zachary, Dhivagaran, Thanansayan, Ramaraju, Harikrishnaa Ba, Wong, Chi Yi, Zuo, Qi Kang, Lapshina, Elizabeth, Mellett, Madeline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815807/
https://www.ncbi.nlm.nih.gov/pubmed/35145560
http://dx.doi.org/10.2217/fvl-2021-0066
Descripción
Sumario:Aim: To evaluate the efficacy and safety of lopinavir–ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events. Results: Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events. Conclusion: Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.

Ejemplares similares